Evidence map›Paper›PMID 26743782›Full record

ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2016

A novel variable exonic region and differential expression of LINC00663 non-coding RNA in various cancer cell lines and normal human tissue samples.

Esra Bozgeyik, Yusuf Ziya Igci, Mevan F Sami Jacksi, Kaifee Arman, Serdar A Gurses, Ibrahim Bozgeyik, Elif Pala, Onder Yumrutas, Ebru Temiz, Mehri Igci

Abstract read
PubMed Publisher
In one paragraph

Article in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Esra BozgeyikFaculty of Medicine, Department of Medical Biology, University of Gaziantep, Gaziantep, Turkey. gyk.esra@gmail.com.
Yusuf Ziya IgciFaculty of Medicine, Department of Medical Biology, University of Gaziantep, Gaziantep, Turkey.
Mevan F Sami JacksiFaculty of Medicine, Department of Medical Biology, University of Gaziantep, Gaziantep, Turkey.
Kaifee ArmanFaculty of Medicine, Department of Medical Biology, University of Gaziantep, Gaziantep, Turkey.
Serdar A GursesFaculty of Medicine, Department of Medical Biology, Zirve University, Gaziantep, Turkey.
Ibrahim BozgeyikDepartment of Medical Biology, Adiyaman University, Adiyaman, Turkey.
Elif PalaDepartment of Medical Biology, Sanko University, Gaziantep, Turkey.
Onder YumrutasDepartment of Medical Biology, Adiyaman University, Adiyaman, Turkey.
Ebru TemizFaculty of Medicine, Department of Medical Biology, University of Gaziantep, Gaziantep, Turkey.
Mehri IgciFaculty of Medicine, Department of Medical Biology, University of Gaziantep, Gaziantep, Turkey.
Gaziantep University · TRAdıyaman University · TRSanko University · TRZirve University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Long non-coding RNAs (lncRNAs) are found to play crucial roles in several biological processes and have been associated with many complex human diseases including cancers. Several lines of evidences indicate that lncRNAs deregulated in many cancer tissues. In this particular study, differential expression of long intergenic non-coding RNA 663 (LINC00663) was demonstrated in various cancer cell lines and healthy human tissues by using RT-PCR and qPCR methods. While expression level of LINC00663 was most prominent in thyroid gland and uterus, it is least expressed in skeletal muscle tissues. Moreover, LINC00663 was found to be differentially expressed in various cancer cells. Particularly, its expression was highly diminished in DU-145, PC3, HGC-27, CRL-1469, A549, MCF7, and BCPAP cancer cells. Also, LINC00663 expression was most prominent in A172 glioblastoma cells. Additionally, a novel splice variant of LINC00663 RNA was also detected. The sequence and Basic Local Alignment Search Tool (BLAST) analysis results revealed the presence of a novel exonic region between exons 2 and 3. Subsequently, five potential splice variants showing high level of variation have been identified. Secondary structures of these variants with minimum free energy were also demonstrated. Furthermore, putative microRNA (miRNA) binding sites to these variants have been shown. In conclusion, LINC00663 was shown to be differentially expressed in various human tissues and cancer cell lines. Also, LINC00663 undergoes alternative splicing and the novel exonic region alters its secondary structure and its interactions with potential targeting miRNAs. The role of LINC00663 in cancer formation further needs to be investigated with a wide range of studies.

Indexed as

A549 CellsBinding SitesCell LineCell Line, TumorExonsGene Expression Regulation, NeoplasticGene Regulatory NetworksGenetic VariationHCT116 CellsHumansHuman Umbilical Vein Endothelial CellsMCF-7 CellsMicroRNAsNeoplasmsRNA, Long NoncodingMicroRNAsRNA, Long NoncodingCancerLINC00663lncRNAmiRNANon-coding RNA

Identifiers

PMID26743782
OpenAlexW2224961962

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.